Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. (Q38608941)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

title

Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Nick Powell

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Mark A Samaan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Polychronis Pavlidis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Emma Johnston

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ben Warner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jonathan Digby-Bell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ioannis Koumoutsos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Steven Fong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Kamal Patel

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Shraddha Gulati

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Lucy Medcalf

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Marlene Sastrillo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Cordella Brown-Clarke

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Johanna Bidewell-Sullivan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Katrina Forsyth

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Emma Lee

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Anna Stanton

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Julie Duncan

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Guy Chung-Faye

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Patrick Dubois

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Simon Anderson

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jeremy Sanderson

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Bu'Hussain Hayee

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Peter M Irving

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

publication date

10 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

Frontline gastroenterology

28 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

196-202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study

28 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Vedolizumab as induction and maintenance therapy for Crohn's disease

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Vedolizumab as induction and maintenance therapy for ulcerative colitis

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Review article: loss of response to anti-TNF treatments in Crohn's disease

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Infliximab for induction and maintenance therapy for ulcerative colitis

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

A simple clinical colitis activity index

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

A simple index of Crohn's-disease activity

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558276

Inflammatory bowel disease: epidemiology and management in an English general practice population

31 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28839909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28839909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/FLGASTRO-2016-100720

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28839909%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference